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Abstract
Background: The identification of Mycobacterium tuberculosis vaccines that elicit a protective immune response in the lungs
is important for the development of an effective vaccine against tuberculosis.
Methods and Principal Findings: In this study, a comparison of intranasal (i.n.) and subcutaneous (s.c.) vaccination with the
BCG vaccine demonstrated that a single moderate dose delivered intranasally induced a stronger and sustained M.
tuberculosis-specific T-cell response in lung parenchyma and cervical lymph nodes of BALB/c mice than vaccine delivered
subcutaneously. Both BCG and a multicomponent subunit vaccine composed of nine M. tuberculosis recombinant proteins
induced strong antigen-specific T-cell responses in various local and peripheral immune compartments. Among the nine
recombinant proteins evaluated, the alanine proline rich antigen (Apa, Rv1 0) was highly antigenic following i.n. BCG and
immunogenic after vaccination with a combination of the nine recombinant antigens. The Apa-induced responses included
induction of both type 1 and type 2 cytokines in the lungs as evaluated by ELISPOT and a multiplexed microsphere-based
cytokine immunoassay. Of importance, i.n. subunit vaccination with Apa imparted significant protection in the lungs and
spleen of mice against M. tuberculosis challenge. Despite observed differences in the frequencies and location of specific
cytokine secreting T cells both BCG vaccination routes afforded comparable levels of protection in our study.
Conclusion and Significance: Overall, our findings support consideration and further evaluation of an intranasally targeted
Apa-based vaccine to prevent tuberculosis.
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Introduction
Mycobacterium tuberculosis, the causative agent of tuberculosis (TB),
continues to ravage mankind throughout the world. According to
the World Health Organization (WHO) an estimated 1.7 million
deaths occurred in 2009 due to TB. Despite a prediction of decline
in global incidence, the number of new TB cases continues to
grow, approaching 10 million in 2010 [1]. The live attenuated
Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccine is the
only TB vaccine currently licensed for human use. The vaccine is
recommended by the WHO and is administered intradermally as
a part of childhood immunization programs in many countries.
Although the BCG vaccine is considered to be effective against
severe pediatric and extra-pulmonary forms of TB, the vaccine has
failed to confer effective protection against adult pulmonary TB in
developing countries. Several clinical and field trials have demon-
strated that the protective efficacy of the vaccine is highly variable.
Development of improved prophylactic and therapeutic interventions
has been emphasized to control the TB pandemic [2,3,4].
Currently, many new TB vaccine candidates are being evaluated
in preclinical studies, and a few have progressed to human clinical
trials, such as recombinant BCG (r-BCG) and subunit vaccines [Stop
TB Partnership Working Group on New TB Vaccines, Vaccine
Pipeline, 2009. http://www.stoptb.org/wg/new_vaccines]. The
potential uses of the vaccines vary in different scenarios depending
on the age, immunocompetence, BCG vaccination history and
exposure to M. tuberculosis or environmental mycobacteria of the
vaccinee. The new vaccines may be used as a pre-exposure priming
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or a post-exposure booster vaccine to prevent disease or even as a
therapeutic vaccine for individuals with active TB [5]. Each of these
strategies is aimed at preventing or eliminating the disease rather than
preventing infection.
Because TB is primarily a respiratory disease, it has been
hypothesized that vaccination directed at the respiratory mucosa
may provide the best opportunity for protection against infection
with the tubercle bacillus. Recent studies have investigated
intranasal (i.n.) vaccination as a means to stimulate mucosal
immunity to TB (reviewed in [6,7]). Intranasal vaccination offers a
needle-free means of a safe and effective immunization against
many mucosal pathogens [8] and has numerous advantages over
the oral route of vaccination [6]. Intranasal instillation in the
nostril also provides a relatively safer strategy compared to deep
lung delivery using inhalation or aerosol vaccination [9]. Because
responses induced by i.n. vaccination are not influenced by
preformed systemic immunity, it also offers an important
advantage over parenteral vaccination, which may be less effective
in individuals who have pre-existing antibodies [10]. This is of
particular importance for vaccination strategies against TB in
mothers and infants in developing countries, where prior Th2
background immunity due to extensive exposure to helminthes
and saprophytic mycobacteria has been hypothesized to sabotage
protective anti-mycobacterial Th1 imprinting and led to BCG
failure [11].
It is envisaged that i.n. vaccination that targets the site of entry
of M. tuberculosis bacilli (i.e., lung) would be able to prevent
infection and subsequent TB disease in the host [12]. Previous
studies in animal models have shown that i.n. delivery of live or
killed BCG vaccine [7,13,14], protein subunit vaccines
[7,15,16,17], lipoglycan-protein conjugate vaccine [18], plasmid
DNA [19], messenger RNA [20], recombinant bacterial vector
[21,22] or viral vector vaccines expressing M. tuberculosis proteins
[23,24] induce a stronger immune response or imparts improved
protection against M. tuberculosis challenge than subcutaneous (s.c.)
or other parenteral routes of vaccination [7,14,23,24]. Both lung
resident and airway luminal T cells have been suggested to play an
important part in i.n. vaccine induced protection against M.
tuberculosis challenge in the mouse model [25,26]. However, the
mechanism of improved protection following i.n. vaccination is not
fully understood and the immune responses generated at different
mucosal and systemic immune compartments by live BCG or
subunit i.n. vaccinations have not been studied in detail.
In this study, we evaluated mycobacterium-specific immune
responses generated at different local and systemic immune sites
following a single, quantitatively moderate but effective protective
dose of live BCG vaccine administered via the i.n. or s.c. route in a
BALB/c mouse model. Our results demonstrate the capacity of
i.n. BCG vaccination to induce strong T-cell responses in the lung
parenchyma and cervical lymph nodes (CLN), and to impart
protection against airway M. tuberculosis challenge. We also
evaluated nine putative M. tuberculosis vaccine candidates for their
recognition by immune cells of the lungs and other local or
systemic compartments following i.n. BCG or multicomponent-
subunit vaccination in order to identify relevant component(s) for a
future mucosal TB vaccine.
Results
Intranasal BCG vaccination induces significantly stronger
type 1 response in the lungs than subcutaneous
vaccination
A moderate dose of BCG (56105 CFUs) has previously been
shown to be protective when administered by the i.n. route [14].
This dose (,0.5–16106 CFUs) is also recommended for preclin-
ical vaccine testing in the mouse model by the s.c. route against
virulent M. tuberculosis challenge (Brennan M. J., personal
communication; when at Food and Drug Administration,
Bethesda, MD, USA). After i.n. or s.c. vaccination with a
moderate dose of BCG, the frequency and distribution of IFN-c,
IL-2, and IL-4 secreting antigen-specific cells in the lungs, spleen
and the respective draining lymph nodes of BALB/c (H-2d) mice
were measured over a course of 12 weeks by ELISPOT assay.
The total number of cells isolated from the different organs did
not significantly differ between diluent-administered control mice
and mice given BCG by either route except for respective draining
lymph nodes. Approximately three-fold more cells were obtained
from the cervical lymph nodes (CLN) of i.n. BCG vaccinated mice
than those of s.c. BCG or diluent-administered mice, while three-
fold to four-fold more cells were isolated from the inguinal lymph
nodes (ILN) of s.c. BCG vaccinated mice than those of i.n. BCG or
diluent-administered mice at 12 weeks. The frequency of cytokine
secreting cells observed in in vitro cultures after stimulation with
tetanus toxoid (TT) compared to those unstimulated was not
statistically different in cell number adjusted ELISPOT assays for
all organs evaluated, indicating that the observed increased
responses after M. tuberculosis whole cell lysate (WCL) stimulation
were mycobacterium specific (data not shown). WCL-specific
cytokine responses of lung and spleen cell cultures were found to
be abrogated by CD4+ T-cell depletion, but were least affected by
depletion of CD8+, cd or NK1.1 T-cells as evaluated at 6 weeks
after i.n. BCG vaccination (data not shown).
Vaccination by i.n. route induced more WCL-specific IFN-c,
IL-2 and IL-4 secreting cells in the lung and draining CLN as
compared to the s.c. route at all three time points evaluated (Fig. 1),
except at the 12 week time point where IL-4-secreting spot
forming units (SFU’s) in the lungs were higher following s.c. BCG
vaccination (p,0.001). Conversely, s.c. BCG vaccination induced
higher WCL-specific IFN-c, IL-2 and IL-4 responses in the ILN,
which drains the flank (the site of s.c. vaccination), and spleen as
compared to i.n. vaccination at all time points evaluated.
However, the splenic cytokine responses of the s.c. group were
not statistically different than those of the i.n. group (p.0.05),
which indicates that i.n. and s.c. BCG vaccination induce
comparable levels of WCL-specific T-cell responses in the spleen.
Overall, while both i.n. and s.c. BCG vaccination produce strong
splenic T-cell responses, i.n. BCG elicits significantly higher type 1
(IFN-c, IL-2) responses in the lungs.
Intranasal BCG vaccination induces significantly higher
levels of nitric oxide (NO) in the lungs than subcutaneous
vaccination
We next evaluated the innate immune response in terms of NO
production induced by either i.n. or s.c. BCG vaccination. Lung
cell cultures of i.n. BCG vaccinated mice produced significantly
higher nitrite levels following WCL stimulation at all the three
time points evaluated than those of s.c. BCG (p,0.0001) or
diluent-administered mice (p,0.0001) (Fig. 2A). Conversely,
spleen cell cultures of s.c. BCG vaccinated mice produced
significantly higher nitrite levels (p,0.05) than those of i.n. BCG
vaccinated mice at the 6 week time point (Fig. 2A).
Furthermore, thoracic and peritoneal exudate cells following i.n.
BCG vaccination were found to produce significantly higher levels
of nitrite after stimulation with WCL (p,0.0001) than those
isolated following s.c. BCG vaccination at 12 weeks (Fig. 2B).
These results suggest the ability of i.n. BCG to induce strong
activation of lung and thoracic innate immune cells such as
macrophages and dendritic cells to produce more NO.
Anti-Tuberculosis Mucosal Vaccine Development
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Figure 1. Kinetics of T-cell responses induced by intranasal or subcutaneous BCG vaccination. The frequencies of M. tuberculosis whole
cell lysate (WCL) specific IFN-c, IL-2 and IL-4 cytokine secreting cells were enumerated in lungs, cervical lymph nodes (CLN), spleen and inguinal
lymph nodes (ILN) of BALB/c mice at 3, 6 and 12 weeks post BCG or diluent (control) vaccination by ELISPOT assay. The frequencies are expressed as
spot forming units (SFUs)/million cells of organ after in vitro stimulation of 16105 cells/well from each organ with WCL for 36–40 h in the presence of
BM-DCs at the ratio of 5:1 organ cells/DC. The results are calculated as means6 standard deviation of three to six determinations of pooled cells from
four mice after subtracting the SFUs from respective unstimulated cultures. Data presented are representative of three similar experiments. Increased
frequencies of WCL-specific IFN-c secreting cells in the lungs of intranasal BCG vaccinated mice were confirmed by evaluation of individual mice
responses at 12 weeks in one of the three experiments. Significant differences among BCG vaccinated groups determined by ANOVA are shown.
*: p,0.05; **: p,0.01; ***: p,0.001 ****: p,0.0001 versus s.c. BCG and #: p,0.05; ##: p,0.01; ###: p,0.001 ####: p,0.0001 versus i.n. BCG.
doi:10.1371/journal.pone.0022718.g001
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Intranasal BCG vaccination induces long-lasting T-cell
responses in different immune compartments
The ability of i.n. BCG vaccination to induce mycobacterium-
specific IFN-c, IL-2 and IL-4 cytokine responses in various local
and distant immune compartments was evaluated by ELISPOT
and lymphocyte proliferation assay at 6 and 30 weeks after
vaccination using two M. tuberculosis antigen preparations, short
term culture filtrate (STCF) and WCL, as in vitro stimulants. STCF
represents a mixture of secreted antigens whereas WCL contains
antigens of subcellular origin. Intranasal BCG vaccination induced
both STCF- and WCL-specific long-term T-cell responses in the
lungs, the local lymph nodes draining the nasal passage (i.e., CLN)
and the spleen as evaluated by ELISPOT assay at 30 weeks post-
vaccination. In these organs T-cell response was characterized by
increased frequencies of IFN-c compared to IL-4 secreting SFU’s
(Fig. 3). The specific cytokine responses were also observed in the
peritoneal cavity (PC), bone marrow (BM) and mesenteric lymph
nodes (MLN) but not in the ILN at 30 week time point (Fig. 3).
Increased frequencies of cytokine secreting SFU’s were observed at
late (30 weeks) compared to early (6 weeks) time point in all these
organs, however, the WCL-specific IFN-c responses in the MLN
declined by 2.3-fold and IL-4 responses in the BM declined by 2.8-
fold at 30 weeks (data not shown). Although cells obtained from
the nasal associated lymphoid tissue (NALT) were not evaluated in
ELISPOT assays, NALT demonstrated comparable levels of
STCF- and WCL-specific proliferation at early (mean stimulation
index (SI) 12.15 and 18.60 at 6 weeks respectively; mean CPM of
unstimulated culture 720) and late (mean SI 10.26 and 12.52 at 30
weeks respectively; mean CPM of unstimulated culture 660) time
points (data not shown). The cells isolated from different immune
compartments of naı¨ve and diluent-administered mice, however,
did not induce any antigen-specific response.
Alanine-proline-rich antigen (Apa, Rv1860) induces
strong IFN-c response following intranasal BCG
vaccination
We compared nine recombinant M. tuberculosis vaccine candidates
(Table 1) [27,28,29,30,31,32,33,34,35,36,37,38,39] for their ability to
be recognized by T cells at 3 and 30 weeks following i.n. vaccination
with BCG. These candidates are known to induce strong systemic
immunity in humans and/or experimental animals when adminis-
tered in different vaccine forms by parenteral route (i.e. percutaneous
or intramascular injection), and impart significant protection against
mycobacterial challenge in different animal models in preclinical
studies (Table 1). Fig. 4 shows the frequency of IFN-c, IL-2 and IL-4
cytokine-secreting cells in lung and spleen following in vitro stimulation
with individual candidates. Among all antigens evaluated, Apa
induced the strongest IFN-c response at the early time point while
Figure 2. Kinetics of NO response induced by intranasal or subcutaneous BCG vaccination. A. The levels of nitrite released after in vitro
stimulation with M. tuberculosis whole cell lysate (WCL) were estimated in lung and spleen cell culture supernatants at 3, 6 and 12 weeks post
vaccination of BALB/c mice by Griess assay. The levels are expressed as mM nitrite/million cells of the organ after 96 h of stimulation with WCL. B.
Nitrite levels produced by WCL-stimulated exudate cells isolated from peritoneal cavity (PC) and thoracic cavity (TC) at 12 weeks. The results are
presented as means 6 standard deviation of three WCL-stimulated independent culture supernatants assayed in duplicate after subtracting the
background nitrite levels from respective unstimulated cultures. The nitrite levels of unstimulated cultures were always less than 5 mM. Significant
differences determined by ANOVA are shown. ****: p,0.0001 versus s.c. BCG and #: p,0.05 versus i.n. BCG.
doi:10.1371/journal.pone.0022718.g002
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GroEL, Apa and Ag85A were the top three inducers of IFN-c
response at the later time point in the lungs (Fig. 4A; panel a, b).
Recognition of all antigens was higher in the lungs at the 3-week time
point than in cells from the spleen (Fig. 4B). The Apa-induced IL-2
response was low as compared to the GroEL-induced response at
both time points evaluated. The frequency of Apa-specific IL-4
producing cells was also less as compared to IFN-c secreting cells in
the lungs and spleen at both 3 and 30 weeks (Fig. 4B, C). Consistent
with the observations in the lungs, higher frequencies of Apa-specific
IFN-c producing cells were observed in the CLN at 3 weeks while
GroEL, Apa and Ag85A induced a stronger IFN-c response at 30
weeks (Fig. S1). As expected, cytokine responses induced by CFP-10
and MPT-64 were either totally absent or very low since these
antigens are absent from the BCG Copenhagen strain used for
vaccination (Fig. 4B, C and S1).
Apa induces strong IFN-c response following intranasal
multicomponent subunit vaccination
The ability of individual vaccine candidates to induce T-cell
responses following multicomponent subunit vaccination was
evaluated. Fig. 4 shows the frequency of IFN-c, IL-2 and IL-4
cytokine secreting cells in lung and spleen after in vitro stimulation
with individual candidates. Following i.n. cocktail vaccination in
Dimethyl-dioctadecyl-ammonium bromide (DDA)-monopho-
sphoryl lipid A (MPL) adjuvants, all nine vaccine candidates were
found to be strongly recognized by T-lymphocytes from the lungs
as evaluated by ELISPOT assay. The top two candidates in terms
of induction of IFN-c secreting cells at the level of the lungs were
Apa and MPT-64 (Fig. 4A; panel c). The antigen recognition
pattern was similar in all the immune compartments evaluated
with the exception of MLN (Fig. 4D and S2). Although Apa
Figure 3. The distribution of T-cell responses in different immune sites after intranasal BCG vaccination. The distribution of M.
tuberculosis whole cell lysate (WCL) and short term culture filtrate (STCF) specific T-cells in local and peripheral immune compartments of BALB/c mice
was investigated at 30 weeks after intranasal BCG vaccination. The frequencies of IFN-c and IL-4 secreting cells in lungs, spleen, cervical lymph nodes
(CLN), peritoneal cavity (PC), bone marrow (BM), mesenteric lymph nodes (MLN), and inguinal lymph nodes (ILN) were enumerated by ELISPOT assay.
The frequencies are expressed as spot forming units (SFUs)/million cells after in vitro stimulation of 16105 cells/well from each organ for 36–40 h in
the presence of BM-DCs at the ratio of 5:1 organ cells/DC. The results are calculated as means 6 standard deviation of three to six determinations of
pooled cells from four mice after subtracting the SFUs from respective unstimulated cultures.
doi:10.1371/journal.pone.0022718.g003














Ag85A Rv3804c 35.55 30.5 05.rEC.04.28.Ag85A 1.37 Mycolyl Transferase/Fibronectin binding [27], [28]
Ag85B Rv1886c 34.45 29.5 05.rEC.04.25.Ag85B 1.43 Mycolyl Transferase/Fibronectin binding [29], [30],
[31]
MPT-64 Rv1980c 24.72 24.0 05.rEC.05.25.MPT64 1.23 Unknown [32], [33]
Pst-S1 Rv0934 38.11 38.0 05.rEC.07.12.Psts1 1.90 Phosphate transporter [34]
Apa Rv1860 32.59 45–47 05.rEC.06.03.ModD 1.77 Fibronectin binding/host cell attachment [35]
GroES Rv3418c 10.67 10.0–12.0 02.rEc.06.12.GroES 0.69 Chaperonin(HSP10)/ATPase [36]
GroEL Rv0440 56.70 65.0 05.rEC.06.08.GroEL2 2.09 Chaperonin (HSP65) [37]
DnaK Rv0350 66.70 70.0 03.rEC.07.21.DnaK 0.86 Chaperonin(HSP70)/ATPase [38]
CFP-10 Rv3874 10.66 10.0 05.rEC.07.12.CFP10 1.67 Unknown/ESAT-6 family member [39]
aObtained through the NIH-TB vaccine testing and research material contract.
bObtained from http://www.ncbi.nlm.nih.gov/entrez.
cMolecular weight of native protein observed in SDS-PAGE analysis.
dEndotoxin levels were determined by Limulus amebocyte lysate (LAL) assay.
doi:10.1371/journal.pone.0022718.t001
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Figure 4. T-cell responses induced by M. tuberculosis antigens in intranasally BCG or multicomponent subunit-vaccinated mice. A.
Representative of nine different M. tuberculosis recombinant antigens-specific IFN-c spot forming units (SFUs) elicited in the lungs in vitro at 3 weeks
(panel a) and 30 weeks (panel b) after BCG vaccination and 2 weeks after last dose of multicomponent subunit vaccination (panel c) of BALB/c mice.
Multicomponent subunit vaccine (MSV) was comprised of a cocktail of nine different proteins in DDA-MPL adjuvant. The IFN-c ELISPOT assay was
developed after stimulation of 16105 or 0.56105 pooled lung cells from four vaccinated mice/well for 40 h with individual antigens or WCL in the
presence of BM-DCs at the ratio of 5:1 lung cells/DC. The WCL was not evaluated (ND) in case of MSV. (B, C and D) The comparative frequencies of
nine antigen-specific IFN-c, IL-2 and IL-4 cytokine secreting cells in lungs and spleen of mice at B. 3 weeks and C. 30 weeks after BCG or D. 2 weeks
after multicomponent subunit vaccination. The assay was performed using 10 mg/ml of individual antigen or total combination (Combi.) for in vitro
stimulation in the presence of BM-DCs. The results are presented as SFUs/million cells of organ and are calculated as means 6 standard deviation of
two to four determinations of pooled cells from four mice after subtracting the SFUs from respective unstimulated cultures. The data presented are
representative of two similar experiments.
doi:10.1371/journal.pone.0022718.g004
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induced both IFN-c and IL-4 producing cells at the majority of
sites following vaccination, the frequency of IL-2 secreting cells
was low. On the other hand, Ag85 complex (A and B), Pst-S1 and
DnaK were observed to be prominent inducers of IL-2 secreting
cells among all candidates evaluated (Fig. 4D and S2). Further-
more, all nine proteins induced strong proliferation of lung cells
after in vitro stimulation as evaluated by 3H thymidine uptake assay
after 72 h of culture. The top three candidates inducing lung cell
proliferation were Pst-S1, Ag85A and Ag85B, similar to
immunogen-specific IL-2 response (data not shown). None of the
immunogens were mitogenic in sham (DDA-MPL) immunized
mice, and their ELISPOT cytokine responses were either equal to
respective unstimulated cultures from vaccinated mice or below
detection limits (data not shown).
The results of multiplexed microsphere-based cytokine immu-
noassays to measure cytokine induction by individual proteins
demonstrated that elevated levels of IL-12(p70), TNF-a, GM-CSF,
IL-4, and IL-10 were secreted in lung cell culture supernatants in
response to Apa stimulation after 72 h of in vitro culture. Among
the purified antigens evaluated, Ag85A, Ag85B and Pst-S1
induced the strongest IL-2 response while IL-2 levels were lowest
in the Apa stimulated culture supernatants (Table 2).
Intranasal Apa vaccine imparts significant protection in a
mouse TB infection model
Having observed that Apa is antigenic with i.n. BCG and
strongly immunogenic in multicomponent subunit vaccinated
mice, we examined the protective efficacy of i.n. Apa/DDA-MPL
subunit vaccine using two different vaccination schedules. In one
experiment, mice were vaccinated with Apa/DDA-MPL vaccine
three times at two-week intervals while in another experiment
three doses were administered at four-week intervals. As intranasal
Ag85A vaccination has been previously shown to be protective in
the mouse model [7,23,24,40], i.n. Ag85A/DDA-MPL subunit
vaccinated mice were included as a positive control for protection
along with i.n. and s.c. BCG vaccinated mice. Four weeks after the
last subunit vaccination, the mice were challenged by intranasal
route with virulent M. tuberculosis and bacterial numbers were
assessed in the lungs and spleen six weeks post challenge.
Consistent with antigenicity and immunogenicity studies, Apa
subunit vaccination imparted significant protection in terms of
reduction of bacterial numbers in the target organs examined
(Fig. 5, which shows the results of two different vaccination
experiments). The CFUs were significantly lower in the lungs and
spleen of Apa vaccinated mice as compared to both unvaccinated
naı¨ve and adjuvant alone immunized control groups (ANOVA;
p,0.05). The level of protection imparted by Apa was comparable
to that induced by Ag85A. Single live BCG vaccination by either
route also imparted significant protection compared to naı¨ve mice,
however, protection imparted by i.n. and s.c BCG vaccination did
not differ significantly from each other. The results comparing
routes of BCG vaccine were similar in three independent
experiments (data not shown). There was also no significant
difference in the number of mycobacterial colonies on plates with
or without 2-thiophene carboxylic acid hydrazide (TCH),
indicating no detectable residual BCG in the lungs or spleens 6
weeks after challenge (data not shown). Subunit vaccination
imparted comparable protection to BCG when mice were
challenged 8 weeks after first subunit dose (Fig. 5A). However,
significantly better protection (Student’s t test and Mann-Whitney
U test p,0.05) was observed with BCG vaccination (i.n. or s.c.) as
compared to Apa and Ag85A-based subunit vaccines when mice
were challenged 12 weeks after first subunit vaccine dose (Fig. 5B).
Intranasal Apa vaccine induces strong in vitro T-cell recall
responses
Use in multicomponent vaccine formulations might result in
both potentiating and suppressive interactions between the
individual components, or competition between various compo-
nents of complex vaccines (such as live BCG or multicomponent
subunit vaccine) for processing and presentation can lead to either
increased or decreased immunogenicity of any component [41].
Therefore, we investigated the magnitude of recall responses
induced by Apa subunit vaccine when administered alone, and
compared with that induced by Ag85A subunit vaccine.
Evaluation of immunogen-specific in vitro recall response at 4
weeks following the last dose (the time interval used for M.
tuberculosis challenge in the protection studies) demonstrated that
both Apa and Ag85A vaccination induce comparable levels of
IFN-c, IL-2 and IL-4 responses in the lungs and spleen (Fig. 6A),
and in the CLN (data not shown), as evaluated by ELISPOT
assay. These results suggest that Apa vaccination induces a similar
magnitude of T-cell recall responses as Ag85A-based subunit
vaccine before challenge. When the lung cells or splenocytes of
vaccinated mice were incubated with bone marrow-derived
dendritic cells that had been pulsed with M. bovis BCG in vitro
Table 2. Th1 and Th2 cytokines induced by intranasal multicomponent subunit vaccination.
Cytokine
Released
(pg/ml)* Protein(s) used for in vitro stimulation
No Ag Ag85A Ag85B MPT-64 Pst-S1 Apa GroES GroEL DnaK CFP-10 Cocktail STCF WCL
IL-2 18.4 859.3 863.4 424.1 739.9 176.6 525.4 393.5 659.9 367.6 700.0 609.0 778.0
IL-12 (p70) BDL 4.2 8.3 24.0 1.0 24.0 BDL 8.3 4.2 BDL 16.2 20.1 31.7
TNF-a 4.1 23.2 32.7 47.0 32.7 47.5 27.9 42.2 23.2 13.7 56.5 58.9 258.6
GM-CSF 75.0 130.1 161.1 162.8 111.9 203.9 136.4 106.9 157.5 96.3 594.7 467.3 753.6
IL-4 2.9 33.3 24.9 42.1 20.3 67.9 13.8 16.2 14.7 15.7 54.0 35.0 44.0
IL-5 193.7 267.1 352.9 266.7 118.6 203.6 212.8 148.4 382.1 209.1 745.4 579.7 876.5
IL-10 43.9 51.3 65.8 55.0 43.9 102.9 51.3 51.3 62.2 43.9 131.5 156.0 399.1
*The results are expressed as mean pg/ml levels in in vitro antigen stimulated duplicate 16106 lung cells/ml of RPMI culture as estimated by multiplexed cytokine bead-
based assay. The standard deviation between replicate wells was less than 10%.
BDL; below detection limit.
doi:10.1371/journal.pone.0022718.t002
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(as a surrogate for M. tuberculosis challenge) a strong IFN-c recall
response was elicited in lung as compared to spleen and was
characterized by increased IFN-c SFU’s compared to IL-4
(Fig. 6B). These results suggest the ability of i.n. Apa and Ag85A
subunit vaccines to induce strong IFN-c recall immune responses
in the lungs after M. tuberculosis challenge.
Discussion
Our study demonstrate that it is possible to engender a robust
mycobacterium-specific immune response in the lungs by i.n.
instillation of a single moderate dose of BCG vaccine, including
strong type 1 (IFN-c and IL-2) lymphocyte responses and
macrophage activation (as measured by increased NO release).
Our results also demonstrate that i.n. BCG vaccination induces
specific T-cell responses in the CLN, which drains the NALT and
nasal cavity, while s.c. delivery produces responses almost
exclusively in the draining ILN. These observations corroborate
the tenet that the immune system is compartmentalized and the
early immunological responses tend to be strongest in compart-
ments most proximal to the site of vaccine administration.
Interestingly, the frequency of antigen-specific cytokine-secret-
ing cells found in the lymph nodes (CLNs and ILNs), a secondary
lymphoid organ where immune responses develop, was low
compared to that found in a nonlymphoid tissue such as the
lung. This may be explained by the propensity of effector and
memory T-cells to migrate out of LNs and preferentially reside in
nonlymphoid organs [42]. In our study, long lasting T cell
immunity was found to be augmented not only in both inductive
(NALT and CLN) and effector sites (lung and spleen) but also in
Figure 5. Protective efficacy of intranasal Apa/DDA-MPL subunit vaccine. In two independent experiments (A and B) groups of BALB/c
mice were vaccinated intranasally with three different doses of M. tuberculosis recombinant Apa or Ag85A in DDA-MPL and compared to
unvaccinated naı¨ve, adjuvant alone and BCG vaccinated controls. In experiment-A three subunit vaccine doses were instilled at two-week intervals
while in experiment-B they were administered at four-week intervals. All groups were challenged by the intranasal route with virulent M. tuberculosis
Erdman either eight weeks (experiment A) or twelve weeks (experiment B) after the first vaccination. Six weeks post-challenge, all mice were
sacrificed and the bacterial burden (CFU’s) was measured in the lungs and spleen. In both experiments data are presented as mean values from five
mice per group and standard deviation of the means are indicated by error bars. Statistical comparisons among the groups were done by one-way
ANOVA and Tukey’s test. Significant differences are shown. **: p,0.01, *: p,0.05 with respect to (wrt) naı¨ve controls, and !!: p,0.01, !: p,0.05 wrt
DDA-MPL adjuvant controls. The significant differences (p,0.05) between the multiple groups were also confirmed by nonparametric Kruskal-Wallis
test.
doi:10.1371/journal.pone.0022718.g005
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an unrelated cavity (peritoneal cavity) and migratory memory T-
cell nesting compartment (BM) [43]. The cytokine responses were
also observed at the level of MLN that drains the gastrointestinal
tract (another mucosal surface), collectively suggesting that i.n.
BCG is capable of inducing immunity in multiple local and
systemic immune compartments.
The ELISPOT results further demonstrated the ability of i.n.
BCG vaccination to induce strong and sustained mycobacterium-
specific immunity, directed toward both secreted and subcellular
fractions of M. tuberculosis. These observations, in part, were in
agreement with ELISPOT results observed by Goonetilleke et. al
[23] using PPD as an in vitro stimulus where peak IFN-c responses
were observed at 12 weeks after parenteral and i.n. BCG
vaccination and were sustained until 24 weeks. However, our
observations differ from those of Chen et. al. [14] who
demonstrated peak IFN-c levels at 3 weeks post i.n. BCG
vaccination that declined rapidly after 6 weeks as measured by
cytokine ELISA using killed BCG as in vitro stimulus.
It has been previously shown that early BCG multiplication
occurs in the draining ILN following s.c. vaccination at the base of
tail [44]. BCG then disseminates in the spleen and lungs after 4
weeks with significantly more bacilli counts in the spleen than in
the lungs [44]. On the contrary, large portion of the total BCG
delivered could be cultured from the lungs within 24 h of i.n. BCG
vaccination [23,45]. This results in more BCG load in the lungs
than in the spleen of mice [45]. Although we have not studied
BCG persistence and dissemination in different local and distant
organs in detail after i.n. or s.c administration, we observed similar
BCG growth kinetics in the lungs and spleen as reported in above
studies over a course of 12 weeks depending on the route of
vaccination (data not shown). These differences in the BCG
bacillary antigenic load in the draining lymph nodes, lungs and
spleen after i.n. and s.c vaccination may account for the differences
observed in the magnitude of specific immune responses in these
organs.
Despite observed differences in the frequencies and location of
specific cytokine secreting T cells both BCG vaccination routes
afforded comparable levels of protection against airway M.
tuberculosis challenge in our study. It can be inferred that the
frequency of T cells in the lungs elicited by s.c. BCG vaccination
was sufficient to afford protection equivalent to that of i.n. BCG in
the lungs. Increased ratio of specific IFN-c to IL-4 SFU’s in the
lungs after i.n. BCG vaccination also did not contribute toward the
enhancement of protection compared to s.c. BCG. These results
suggest that the protection imparted by a single moderate dose of
BCG vaccine is independent of route of vaccination in our model.
It also indicates that the readout of correlate of protection against
TB may not be as simple as induction of dominant type 1 cytokine
response.
Our results are contrary to the findings of earlier studies in
which i.n. BCG afforded better protection than s.c. vaccination
[14,46]. However, these results in part correlate with the findings
of Goonetilleke et. al. [23], who demonstrated that a single i.n. dose
of BCG did not differ in the degree of protection afforded and that
two sequential i.n. BCG doses are required to afford superior
protection compared to parenteral BCG vaccine administered
using similar double dosing strategy. In different studies,
intravenous, oral, rectal and aerosol BCG administration using
Figure 6. Recall responses induced by Apa subunit vaccination. BALB/c mice were vaccinated with three different doses of Apa in DDA-MPL
adjuvant at two week intervals and compared with Ag85A/DDA-MPL vaccinated and naı¨ve (unvaccinated) and sham (adjuvant only) vaccinated
control mice. Eight weeks after first dose (or four weeks after last dose), before M. tuberculosis challenge, mice were sacrificed and immunogen-
specific T-cell responses were investigated in vitro in the lungs and spleen by ELISPOT assay. The frequencies IFN-c, IL-2 and IL-4 cytokine-secreting
cells are expressed as spot forming units (SFUs)/million cells of organ after in vitro restimulation of 16105 cells/well from each organ with either A.
respective immunogen pulsed or B. M. bovis BCG Copenhagen infected BM-DCs (multiplicity of infection 1:1) at the ratio of 5:1 organ cells/DC for
40 h. The results are calculated as means 6 standard deviation of triplicate determinations of pooled cells from four mice after subtracting the SFUs
from respective unstimulated cultures.
doi:10.1371/journal.pone.0022718.g006
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single dose imparted similar protection against M. tuberculosis
[47,48,49]. It has been shown that BCG vaccination using wide
range of dose induces varying magnitude and quality of immune
responses but imparts similar levels of protection [50,51]. Thus,
the route of application and consequently the dissemination and
tissue localization of BCG following a single vaccination may have
minor impact on protective immunity against TB [49].
However, similar conclusion may not be drawn for non-
multiplying subunit or killed vaccines and detailed studies
evaluating effect of route, dose and delivery system on the
protection imparted by individual subunit vaccines are required.
Mice vaccinated via i.n. route using culture filtrate proteins-based
subunit vaccine were found to be better protected as compared to
s.c. route [52], and the dose of a subunit vaccine formulation has
been shown to critically influence its immunogenicity and
protective efficacy [53]. Furthermore, one cannot totally discount
the benefit of mucosal immunity induced by a single i.n. BCG as
the compartmentalization of immune responses generated in the
lungs and respiratory tract has been shown to have positive
implications for the development of booster subunit vaccines and
effective prime-boost vaccination strategies [23,25].
Central to the development of a subunit vaccine would be
identification of M. tuberculosis proteins that can effectively prime
mycobacterium-specific immunity in the respiratory tract. In-
creased immune responses in the lungs and CLN after i.n.
vaccination enabled us to identify M. tuberculosis proteins
recognized by the immune cells of these organs. Among the nine
proteins evaluated in this study, Apa and GroEL were found to be
highly antigenic in BCG-vaccinated mice as measured by IFN-c
response in different immune compartments. Other polypeptides
which induced prominent responses following i.n. BCG vaccina-
tion were Ag 85 complex proteins and Pst-S1. The magnitude and
hierarchy of these antigen-specific responses varied at different
time points, which may be due to stage specific differential
expression of antigens in vivo or variation in subcellular localization
of bacilli resulting in the temporal differences in the antigen profile
recognized. Of note, Apa, a 45/47 kDa cell surface or secreted
glycoprotein, GroEL, a 65 kDa cytosolic heat shock protein and
Ag85 complex, 30–32 kDa cell surface or secreted polypeptides,
have all been previously shown to be highly antigenic in humans
[35,54,55] with different stages of M. tuberculosis infection.
The Apa complex is composed of mannosylated proteins [56]
with up to nine identified glycoforms [57,58]. APA is also known
as M. tuberculosis protein (MPT)-32 (calculated molecular mass
32 kDa), ModD (putative involvement in molybdate uptake) or
fibronectin attachment protein (FAP), and can mediate bacterial
attachment to host cells as a potential adhesin [59]. Both Apa and
Ag85 complex proteins have been found to be released into
phagosomes and other subcellular compartments of M. bovis BCG
infected macrophages [60]. The recombinant Apa homolog has
also been found to activate dendritic cells and induce Th1
polarization [61]. It is noteworthy that Apa is predominantly
recognized following vaccination with live but not dead BCG
organisms [62]. Moreover, monoclonal antibody against Apa has
been previously shown to abrogate the attachment and internal-
ization of BCG by human bladder tumor cells and stable binding
of BCG to bladder mucosa via FAP was necessary for the
expression of BCG-induced antitumor activity [63,64]. Overall,
this suggests that APA-specific responses might contribute to
protective responses induced by live multiplying BCG.
In parallel with the responses following i.n. BCG vaccination,
Apa was also highly immunogenic after intranasal multicomponent
subunit vaccination. The immune responses induced by Apa were
characterized by strong in vitro type1 and type 2 cytokine response.
The Apa also induced strong antibody response characterized by
elevated specific serum IgG and nasal lavage IgA as determined
using ELISA and cytotoxic T-cell response (mean cytotoxicity 30%)
as evaluated by neutral red uptake assay (data not shown).
It has been previously shown that deglycosylation of Apa affects
its capacity to stimulate in vitro proliferation of T-cells from guinea
pigs following s.c. BCG vaccination [58]. However, i.n. recombi-
nant (unglycosylated) Apa subunit vaccinated mice could signifi-
cantly inhibit M. tuberculosis growth in the lungs and spleen similar to
that of Ag85A-based subunit vaccine (this study) and a s.c. prime-
boost vaccination strategy using recombinant MVA expressing Apa
has been previously shown to protect guinea pigs against virulent M.
tuberculosis challenge [35]. These observations along with the strong
antigenicity and immunogenicity obtained from the recombinant
(unglycosylated) Apa used in this study warrants further evaluation
in comparison with its native (glycosylated) counterpart.
The significant level of protection afforded in animal models by
Ag85A, another fibronectin binding protein, after i.n. vaccination
in previous studies [23,24] and strong T cell mediated immuno-
genicity elicited by Apa vaccination in the respiratory and other
immune compartments leading to comparable protection against
M. tuberculosis challenge in the current study bodes well for use of
these molecules as components of future mucosal TB vaccines.
Overall, findings of this study strongly support further evaluation
of mucosally targeted Apa-based vaccine to prevent tuberculosis.
Materials and Methods
Animals
Specific-pathogen-free, 6–8 weeks old female BALB/c (H-2d)
mice purchased from Harlan Sprague Dawley (Indianapolis, IN)
were used in the study. All mice were housed in Biosafety Level-II
or -III animal facility, as per the requirement of the experiment.
All animals were fed on a standard pellet diet and water ad libitum.
Experiments performed were in accordance with the approved
animal protocols (permit numbers: 1422SHINMOUC, 1664SAB-
MOUC, 1490SABMOUC and 1847SABMOUC) and guidelines
of the Institutional Animal Care and Use Committee (IACUC) of
CDC, Atlanta.
BCG vaccine and M. tuberculosis culture
The BCG (Copenhagen) vaccine and M. tuberculosis Erdman
were provided as a TB preclinical vaccine reference standard and
challenge strain, respectively by the Center for Biologics
Evaluation and Research, Food and Drug Administration
(FDA), Bethesda, USA.
M. tuberculosis antigens
Nine recombinant M. tuberculosis H37Rv proteins (Table 1),
whole cell lysate (WCL), and total short term culture filtrate
proteins (STCF) were obtained through the TB Vaccine Testing
and Research Material (TBVTRM) contract funded by National
Institute of Health (NIH)/National Institute of Allergy and
Infectious Diseases (NIAID) at Department of Microbiology,
Immunology and Pathology, Colorado State University, Fort
Collins, Colorado. Nine recombinant plasmids containing M.
tuberculosis genes that encode the nine proteins (Table 1) were also
obtained. Some of the recombinant proteins were further
expressed in E. coli BL-21 (DE3) and purified as per the protocol
provided by the TBVTRM contract.
BCG and subunit vaccination
Lyophilized BCG vaccine was resuspended in vaccine diluent
(diluted Sauton medium) provided by the supplier (Statens Serum
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Institute, Copenhagen, Denmark). For s.c. vaccination, 50 ml of a
BCG suspension (76105 CFUs) was injected above the gluteus
superficialis and biceps femoralis muscles of both hind legs using a
26 gauge needle. Intranasal administration was carried out by
applying a total of 30 ml of BCG vaccine (76105 CFUs) to the
external nares (15 ml per nostril) using a fine tip micropipette and
allowing the mouse to inhale the suspension into the lungs
naturally. BCG vaccine diluent was used as a control for either
route of vaccination.
For multicomponent subunit vaccination, mice were immunized
by the i.n. route three times at 2-week intervals as described above
except using 90 mg of recombinant M. tuberculosis protein mixture
per dose [10 ug of each immunogen emulsified in DDA (250 mg/
dose, Sigma-Aldrich, St. Louis, MO) and MPL (derived from
Salmonella minnesota Re 595; 25 mg/dose, Sigma-Aldrich)]. The
emulsion was prepared as described previously [28]. Briefly, MPL
was first mixed with endotoxin-free sterile water (Burdick &
Jackson, Muskegon, MI) containing 0.2% triethylamine (Fisher
Scientific, Fair Lawn, NJ). The mixture was heated in a 70uC
water bath for 30 s and then sonicated for 30 s. The heating and
sonicating procedure was repeated twice. To prepare the
emulsion, DDA was suspended in sterile water and a homoge-
neous dispersion of the powder was obtained by heating the
suspension at 80uC for 5–10 min in water bath. After cooling to
room temperature, MPL and antigens were mixed with DDA just
before use. The sham-immunized mice received PBS (pH 7.2)
emulsified in DDA-MPL.
Collecting tissues
Following vaccination, mice were bled by cardiac puncture
under anesthesia and sacrificed at different time points. Lungs,
spleen, NALT, CLN (superficial), ILN, MLN and femur and tibial
bone marrow (BM) were aseptically removed and placed into
RPMI 1640 supplemented with 100 IU ml21 penicillin,
50 mg ml21 streptomycin, 1 mM L-glutamine, 25 mM HEPES,
1 mM sodium pyruvate, 561025 M ß-mercaptoethanol, vitamins
and nonessential amino acids (Gibco-Invitrogen, Grand Island,
NY) and 10% endotoxin-tested heat-inactivated fetal calf serum
(FCS; Atlas Biologicals, Fort Collins, CO). Thoracic and
peritoneal exudate cells were isolated by washing the respective
cavities with RPMI 1640 media. In each case, the respective
lymphoid or extra-lymphoid organs or cavity washings were
collected from 4 mice for each treatment group and cells were
extracted for analysis of in vitro M. tuberculosis antigen-specific
cellular responses.
Isolation of immune cells
To isolate lung cells, mice were bled by cardiac puncture under
anesthesia and their lungs were perfused via the right ventricle
with PBS containing 10 U ml21 heparin to remove intravascular
leukocytes. The lungs were then perfused with an enzyme mixture
containing 1 mg/ml collagenase type IV (Sigma-Aldrich) and
25 U ml21 DNase (Roche, Penzberg, Germany) in supplemented
RPMI and sliced into small pieces in a sterile dish and the
fragments were incubated in the enzyme mixture at 37uC for 1 h.
The digested lung fragments were pressed with a 5 ml syringe
plunger through a 70-mm pore size cell strainer (BD Falcon,
Bedford, MA) to obtain a single cell suspension and the
erythrocytes were lysed with RBC lysis buffer (eBioscience, San
Diego, CA) for 4–5 min at room temperature. The lung cells were
washed, recovered by centrifugation, and resuspended in supple-
mented RPMI for counting using an automated cell counter
(Countess, Invitrogen, Carlsbad, CA) employing the trypan blue
dye exclusion method. The NALT was isolated as described
previously by Asanuma et. al. [65] and BM was isolated by flushing
cavities of femurs and tibias with RPMI. The single cell
suspensions of spleen, lymph nodes, BM or NALT were obtained
by gently grinding the respective organs through a 70-mm cell
strainer into 10–20 ml supplemented RPMI. The cell suspensions
were centrifuged at 3006g for 10 min and the erythrocytes were
removed by treatment with RBC lysis buffer when necessary. Cells
were washed several times with fresh RPMI and the cell
concentration was adjusted accordingly.
BM derived dendritic cells (DCs)
These were generated from naı¨ve BALB/c BM according to the
procedure described by Inaba et. al. [66]. A granulocyte-
macrophage colony stimulating factor (GM-CSF) expressing
J558L cell line (supplied by Dr I. Mellman, Yale University
School of Medicine, New Haven, CT) was used as a source of
GM-CSF. Supplemented RPMI containing recombinant interleu-
kin (IL)-4 (20 ng ml21, PreproTech, Rocky Hill, NJ) and GM-
CSF (1:200 dilutions) was used to culture BM DCs. Flow
cytometric analysis revealed that .90% of cells were CD11c+
after 7 days of culture.
Enzyme linked immuno-spot (ELISPOT) assay
Commercially available interferon (IFN)-c, IL-2, and IL-4 kits
(Mouse ELISPOT set; BD-Biosciences, San Diego, CA) were used
to enumerate frequencies of M. tuberculosis antigen-specific cells
according to the manufacturer’s protocol. In brief, 96 well
ELISPOT plates were coated with 100 ml of 5 mg ml21 capture
antibody in PBS (pH 7.2) and incubated overnight at 4uC. Free
binding sites were blocked with 200 ml of supplemented RPMI
containing 10% FCS for 2 h at room temperature. Cell
concentration was adjusted to 0.5–26106 cells ml21 for all sites
except 0.56106 cells ml21 for NALT and added to appropriate
wells. BM-derived DCs were added at the ratio of 5:1 immune
cells/DC to supplement the antigen presenting cells already
present in the cell suspension. For each treatment group, cells were
stimulated in triplicate with either 10 mg ml21 of individual
recombinant purified M. tuberculosis antigens, antigen combination,
STCF, WCL, Concanavalin A (Con-A; Sigma-Aldrich), Tetanus
toxoid (TT; Calbiochem-EMD Biosciences, San Diego, CA),
Isopentenyl pyrophosphate (IPP; Sigma-Aldrich) or medium alone
in a 100 ml volume. After 36–40 h of incubation at 37uC in a
humidified atmosphere containing 5% CO2, the unattached cells
were aspirated from the well and the remaining cells were lysed
with distilled water. The wells were washed again with PBS
containing 0.05% Tween-20 (PBS-T) and the site of cytokine
secretion was detected with a biotin-labeled anti-mouse cytokine
antibody and horseradish peroxidase-conjugated streptavidin. The
enzyme reaction was developed using 3-amino-9-ethylcarbazole
(AEC) substrate reagent set (BD-Bioscience). The number of spot
forming units (SFUs) per well were counted automatically using an
ELISPOT reader (Cellular Technology Limited, Cleveland, OH).
The number of spots specific for each antigen preparation was
calculated by subtracting the number of spots that formed in the
absence of added antigen from the number that formed in its
presence.
Lymphocyte proliferation assay
Cells isolated from different sites were seeded in sterile 96-well
flat-bottom tissue culture plates (Costar, Corning, NY) at 16106
cells ml21 in 100 ml of supplemented RPMI-1640. BM derived
DCs were used at the ratio of 5:1 lymphocytes/DC as described
for ELISPOT assay in appropriate experiments. For each
treatment group, cells were stimulated in triplicate with either
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100 ml of 10 mg ml21 of purified recombinant M. tuberculosis
antigens, antigen combination, WCL, STCF, or Con-A in
supplemented RPMI as a positive control for cell viability and
reactivity or medium alone as a negative control. Cultures were
incubated in a humid atmosphere containing 5% CO2 at 37uC for
72 h. 1 mCi of 3H-thymidine (Perkin Elmer, Wellesley, MA) was
added to each well and after 18–20 h incubation the cells were
harvested on glass fiber filters (Perkin Elmer) using an automated
cell harvester (TOMTEC, Inc. Hamden, CT). Once dry, the
radioactivity incorporated was counted using a b-scintillation
counter (Perkin Elmer). The proliferation was expressed as mean
counts per minutes (CPM) of antigen stimulated cultures after
subtracting mean counts per minutes of cultures without antigen
and the stimulation index (SI) was calculated by dividing mean
counts per minute in antigen-stimulated wells by mean counts per
minute in unstimulated wells.
Determination of nitrite accumulation
Nitrite (NO2
2) accumulation in the supernatant of cultured cells
was measured as an indicator of nitric oxide (NO) production by a
Griess assay using a sodium nitrite standard as described
previously [55]. Supernatants (100 ml) from 16106 cells ml21 of
each condition stimulated with 10 mg ml21 WCL, E. coli LPS-
TLR-4 ligand (InvivoGen, San Diago, CA) or RPMI medium
alone after 96 h of culture at 37uC were assayed in triplicate, and
the absorbance was measured at 550 nm.
Multiplexed microsphere-based cytokine immunoassay
The supernatants of cell cultures stimulated with M. tuberculosis
antigens were harvested after 72 h of culture, centrifuged, filtered,
and stored at 270uC, and used in a multiplexed microsphere-
based cytokine immunoassay. Duplicate cell culture samples were
assayed in duplicate using a Bio-Plex Cytokine Assay kit (Bio-Rad
Laboratories; Hercules, CA) as per the manufacturer’s instruc-
tions. The median fluorescence intensity (MFI) was determined on
a Bio-Plex 100 instrument equipped with Bio-Plex Manager v. 4.0
software. The concentrations for IL-2, IL-4, IL-5, IL-10, IL-12
p70, TNF-a and GM-CSF are reported as pg/ml.
Experimental infections. Protective efficacy was evaluated
in two separate challenge experiments. In both cases, mice were
challenged by the intranasal inhalation route to deliver
46104 CFUs of M. tuberculosis Erdman by instilling a total of
30 ml in to the external nares (15 ml per nostril). At 48 h following
challenge, approximately 0.5% of the total CFUs delivered could
be cultured from the lungs. In the first experiment, mice were
immunized intranasally with three doses of recombinant Apa or
Ag85A (10 mg/dose) in DDA-MPL adjuvant at 2-week intervals.
The immunogen-specific recall immunity was investigated 4 weeks
after the last dose in vitro in a separate experiment using similar
immunization protocol. In the second experiment, mice received
three doses of subunit vaccine at 4-week intervals. In both cases,
mice were challenged 4 weeks after the last immunization and
CFU levels were evaluated at week 6 post-infection. Bacterial
levels were determined by plating serial dilutions of lung and
spleen homogenates onto Middlebrook 7H10 agar (BD-
Biosciences) supplemented with OADC and TCH (2 mg ml21).
Colonies were enumerated after 4 weeks of incubation at 37uC
and numbers were expressed as the log10 values of the geometric
mean for five mice. Protective efficacy promoted by the Apa/
DDA-MPL and Ag85A/DDA-MPL subunit vaccines was
compared with the protective levels afforded by the conventional
TB vaccine, BCG. To this end, mice received one dose
(76105 CFUs) of BCG injected subcutaneously on the hind legs
or instilled intranasally (as described above) at the time of first dose
of subunit vaccines and protective efficacy was analyzed in parallel
with the subunit vaccinated groups.
Statistical analysis
The data obtained from immunological assays were analyzed
using a Student’s t-test and analysis of variance (ANOVA).
Differences between the different groups in the protection
experiments were assessed by one-way ANOVA of the log10 CFUs
followed by Tukey’s test and also by its nonparametric equivalent
Kruskal-Wallis test (for comparison of more than two groups) and
Mann-Whitney U test (for comparison of two groups). A value of
p,0.05 was considered significant.
Supporting Information
Figure S1 T-cell responses in the CLN of intranasally
BCG-vaccinated mice. The frequencies of nine antigen-specific
Th1 (IFN-c and IL-2) and Th2 (IL-4) cytokine secreting cells in the
CLN of i.n. BCG vaccinated mice at early (3 weeks) and late (30
weeks) time points were enumerated by ELISPOT assay and
expressed as SFUs/million cells. The assay was developed after
stimulation of 16105 cells/well for 36–40 h with individual
antigens in the presence of BM-DCs at the ratio of 5:1 lung
cells/DC. The results are calculated as means 6 standard
deviation of duplicate determinations of pooled cells from four
mice after subtracting the SFUs from respective unstimulated
cultures. Data presented are representative of two separate
experiments each consisting of four mice per group.
(TIF)
Figure S2 T-cell responses in the CLN, PC and MLN of
intranasally multicomponent subunit-vaccinated mice.
The frequencies of immunogen-specific Th1 (IFN-c and IL-2) and
Th2 (IL-4) cytokine-secreting cells in the CLN, PC and MLN two
weeks after intranasal multicomponent vaccination as enumerated
by ELISPOT assay using BM-DCs as antigen presenting cells in
the cell culture and expressed as SFUs/million cells of organ. The
results are presented as means 6 standard deviation of four
determinations of pooled cells from four mice after subtracting the
SFUs from respective unstimulated cultures.
(TIF)
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